

Evolving standards of care and new challenges in the m
cancer

Ca-A Cancer Journal for Clinicians

70, 355-374

DOI: 10.3322/caac.21634

Citation Report

#	ARTICLE	IF	CITATIONS
1	The evolution and advances of biomarker use in clinical trials for breast cancer treatment—a narrative review. <i>Translational Breast Cancer Research</i> , 0, 2, 6-6.	0.4	0
2	Targeting transcription of MCL-1 sensitizes HER2-amplified breast cancers to HER2 inhibitors. <i>Cell Death and Disease</i> , 2021, 12, 179.	6.3	11
3	HER2-PI9 and HER2-I12: two novel and functionally active splice variants of the oncogene HER2 in breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 2893-2912.	2.5	2
4	Trans-(α^*)-Kusunokinin: A Potential Anticancer Lignan Compound against HER2 in Breast Cancer Cell Lines?. <i>Molecules</i> , 2021, 26, 4537.	3.8	5
5	Adjuvant Photodynamic Therapy, Mediated via Topical Versus Systemic Administration of 5 α -Aminolevulinic Acid for Control of Murine Mammary Tumor after Surgical Resection. <i>Photochemistry and Photobiology</i> , 2022, 98, 117-126.	2.5	1
6	Loss of HER2-positivity following neoadjuvant targeted therapy for breast cancer is not associated with inferior oncologic outcomes. <i>Journal of Surgical Oncology</i> , 2021, 124, 1224-1234.	1.7	9
7	Efficacy and Safety of Anti-HER2 Agents in Combination With Chemotherapy for Metastatic HER2-Positive Breast Cancer Patient: A Network Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 731210.	2.8	5
8	CDKN1C as a prognostic biomarker correlated with immune infiltrates and therapeutic responses in breast cancer patients. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 9390-9401.	3.6	10
9	Prognostic Score for De Novo Metastatic Breast Cancer With Liver Metastasis and Its Predictive Value of Locoregional Treatment Benefit. <i>Frontiers in Oncology</i> , 2021, 11, 651636.	2.8	4
10	Adverse Drug Reactions with HER2-Positive Breast Cancer Treatment: An Analysis from the Italian Pharmacovigilance Database. <i>Drugs - Real World Outcomes</i> , 2022, 9, 91-107.	1.6	15
11	Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1+ tucatinib/placebo in patients with residual HER2-positive invasive breast cancer. <i>Future Oncology</i> , 2021, 17, 4665-4676.	2.4	8
12	Comparing Biomarkers for Predicting Pathological Responses to Neoadjuvant Therapy in HER2-Positive Breast Cancer: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 731148.	2.8	5
13	Large-scale genomic sequencing reveals adaptive opportunity of targeting mutated PI3K α in early and advanced HER2-positive breast cancer. <i>Clinical and Translational Medicine</i> , 2021, 11, e589.	4.0	6
14	Establishment of a tumor immune microenvironment-based molecular classification system of breast cancer for immunotherapy. <i>Aging</i> , 2021, 13, 24313-24338.	3.1	2
15	Sociodemographic and Clinical Predictors of Neoadjuvant Chemotherapy in cT1-T2/NO HER2-Amplified Breast Cancer. <i>Annals of Surgical Oncology</i> , 2022, 29, 3051-3061.	1.5	3
16	Clinical Outcomes in Breast Cancer Patients with HER2-Positive, Node-Negative Tumors (≥ 3 cm). <i>Breast Care</i> , 0, , .	1.4	0
17	Neoadjuvant pyrotinib plus trastuzumab and nab-paclitaxel for HER2-positive early or locally advanced breast cancer: an exploratory phase II trial. <i>Gland Surgery</i> , 2022, 11, 216-225.	1.1	7
18	Decitabine potentiates efficacy of doxorubicin in a preclinical trastuzumab-resistant HER2-positive breast cancer models. <i>Biomedicine and Pharmacotherapy</i> , 2022, 147, 112662.	5.6	14

#	ARTICLE	IF	CITATIONS
19	The Pharmacological Mechanisms of Xiaochaihutang in Treating Breast Cancer Based on Network Pharmacology. <i>Contrast Media and Molecular Imaging</i> , 2022, 2022, 1-11.	0.8	5
20	Margetuximab Versus Trastuzumab in Patients With Advanced Breast Cancer: A Cost-effectiveness Analysis. <i>Clinical Breast Cancer</i> , 2022, 22, e629-e635.	2.4	4
21	Breast Cancer Phenotype Associated With Li-Fraumeni Syndrome: A Brazilian Cohort Enriched by TP53 p.R337H Carriers. <i>Frontiers in Oncology</i> , 2022, 12, 836937.	2.8	8
22	HER2-Altered Non-Small Cell Lung Cancer: Biology, Clinicopathologic Features, and Emerging Therapies. <i>Frontiers in Oncology</i> , 2022, 12, 860313.	2.8	12
23	Flubendazole induces mitochondrial dysfunction and DRP1-mediated mitophagy by targeting EVA1A in breast cancer. <i>Cell Death and Disease</i> , 2022, 13, 375.	6.3	13
24	Relationship Between Breast and Axillary Pathologic Complete Response According to Clinical Nodal Stage: A Nationwide Study From Korean Breast Cancer Society. <i>Journal of Breast Cancer</i> , 2022, 25, 94.	1.9	4
25	Dual-Targeted Therapy Circumvents Non-Genetic Drug Resistance to Targeted Therapy. <i>Frontiers in Oncology</i> , 2022, 12, 859455.	2.8	2
26	Longitude Variation of the microRNA-497/FGF-23 Axis during Treatment and Its Linkage with Neoadjuvant/Adjuvant Trastuzumab-Induced Cardiotoxicity in HER2-Positive Breast Cancer Patients. <i>Frontiers in Surgery</i> , 2022, 9, .	1.4	1
27	Using population-based data to evaluate the impact of adherence to endocrine therapy on survival in breast cancer through the web-application BreCanSurvPred. <i>Scientific Reports</i> , 2022, 12, 8097.	3.3	6
28	HER2-MCNN: a HER2 classification method based on multi convolution neural network. , 2021, , .		0
29	Breast cancer in the era of precision medicine. <i>Molecular Biology Reports</i> , 2022, 49, 10023-10037.	2.3	19
30	Determining the Optimal (Neo)Adjuvant Regimen for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Regarding Survival Outcome: A Network Meta-Analysis. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	0
31	Evaluation of Safety and Clinically Relevant Drug-Drug Interactions with Tucatinib in Healthy Volunteer's. <i>Clinical Pharmacokinetics</i> , 2022, 61, 1417-1426.	3.5	7
32	Efficacy and Safety of Pyrotinib in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Multicenter, Retrospective, Real-World Study. <i>OncoTargets and Therapy</i> , 0, Volume 15, 1067-1078.	2.0	2
33	Imaging strategies for receptor tyrosine kinase dimers in living cells. <i>Analytical and Bioanalytical Chemistry</i> , 2023, 415, 67-82.	3.7	2
35	A multicentre single arm phase 2 trial of neoadjuvant pyrotinib and letrozole plus dalpiciclib for triple-positive breast cancer. <i>Nature Communications</i> , 2022, 13, .	12.8	11
36	Efficacy and safety of pyrotinib and radiotherapy vs. pyrotinib-based therapy in patients with HER2+ breast cancer with brain metastasis: a retrospective cohort study. <i>Annals of Translational Medicine</i> , 2022, 10, 1228-1228.	1.7	1
37	HDACs/mTOR inhibitor synergizes with pyrotinib in HER2-positive pancreatic cancer through degradation of mutant P53. <i>Cancer Cell International</i> , 2022, 22, .	4.1	2

#	ARTICLE	IF	CITATIONS
38	A Dual-Responsive STAT3 Inhibitor Nanoprodrug Combined with Oncolytic Virus Elicits Synergistic Antitumor Immune Responses by Igniting Pyroptosis. <i>Advanced Materials</i> , 2023, 35, .	21.0	28
39	Characteristics, treatment and outcomes of HER2 positive male breast cancer. <i>American Journal of Surgery</i> , 2023, 225, 489-493.	1.8	2
40	The Pharmacokinetics and Safety of Tucatinib in Volunteers with Hepatic Impairment. <i>Clinical Pharmacokinetics</i> , 2022, 61, 1761-1770.	3.5	3
41	PTEN rs701848 Polymorphism is Associated with Trastuzumab Resistance in HER2-positive Metastatic Breast Cancer and Predicts Progression-free Survival. <i>Clinical Breast Cancer</i> , 2023, 23, e131-e139.	2.4	3
42	Data on 2D culture characterisation of potential markers in human HER2-positive breast cancer cell lines. <i>Data in Brief</i> , 2023, 46, 108880.	1.0	0
43	Bioinformatics combined with clinical data to analyze clinical characteristics and prognosis in patients with HER2 low expression breast cancer. <i>Gland Surgery</i> , 2023, .	1.1	0
44	Challenges and future of HER2-positive gastric cancer therapy. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	3
45	Radiogenomic analysis of prediction HER2 status in breast cancer by linking ultrasound radiomic feature module with biological functions. <i>Journal of Translational Medicine</i> , 2023, 21, .	4.4	8
46	Resistance to Antibody-Drug Conjugates Targeting HER2 in Breast Cancer: Molecular Landscape and Future Challenges. <i>Cancers</i> , 2023, 15, 1130.	3.7	7
47	IBIS: identify biomarker-based subgroups with a Bayesian enrichment design for targeted combination therapy. <i>BMC Medical Research Methodology</i> , 2023, 23, .	3.1	1
48	Pathological complete response and prognosis after neoadjuvant chemotherapy in patients with HER2-low breast cancer. <i>Annals of Diagnostic Pathology</i> , 2023, 64, 152125.	1.3	2
49	Potential roles and molecular mechanisms of bioactive ingredients in <i>Curcumae Rhizoma</i> against breast cancer. <i>Phytomedicine</i> , 2023, 114, 154810.	5.3	8
50	Novel roles of RNA-binding proteins in drug resistance of breast cancer: from molecular biology to targeting therapeutics. <i>Cell Death Discovery</i> , 2023, 9, .	4.7	6
51	Survival benefit and biomarker analysis of pyrotinib or pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer: a pooled analysis of two phase I studies. <i>Biomarker Research</i> , 2023, 11, .	6.8	2
52	The role of irreversible pan-HER tyrosine kinase inhibitors in the treatment of HER2-Positive metastatic breast cancer. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	1
53	Molecular landscape and emerging therapeutic strategies in breast cancer brain metastasis. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592311659.	3.2	0
54	Targeted RASSF1A expression inhibits proliferation of HER2-positive breast cancer cells <i>in vitro</i> . <i>Experimental and Therapeutic Medicine</i> , 2023, 25, .	1.8	0
55	Deep learning radiomics model based on breast ultrasound video to predict HER2 expression status. <i>Frontiers in Endocrinology</i> , 0, 14, .	3.5	6

#	ARTICLE	IF	CITATIONS
56	Manufacture and evaluation of a HER2-positive breast cancer immunotoxin 4D5Fv-PE25. Microbial Cell Factories, 2023, 22, .	4.0	0
57	A Phase II Study of Neoadjuvant PLD/Cyclophosphamide and Sequential <i>nab</i> -Paclitaxel Plus Dual HER2 Blockade in HER2-Positive Breast Cancer. Oncologist, 2024, 29, e15-e24.	3.7	1
58	The preclinical study of 177Lu-DOTA-LTVSPWY as a potential therapeutic agent against HER2 overexpressed cancer. Annals of Nuclear Medicine, 2023, 37, 400-409.	2.2	0
59	Analysis of clinical features, genomic landscapes and survival outcomes in HER2-low breast cancer. Journal of Translational Medicine, 2023, 21, .	4.4	1
60	Trastuzumab-resistant breast cancer cells-derived tumor xenograft models exhibit distinct sensitivity to lapatinib treatment in vivo. Biological Procedures Online, 2023, 25, .	2.9	2
61	Emerging insights into mechanisms of trastuzumab resistance in HER2-positive cancers. International Immunopharmacology, 2023, 122, 110602.	3.8	3
62	Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients. Breast Cancer Research and Treatment, 2023, 202, 313-323.	2.5	1
63	Multiparametric MRI and Radiomics for the Prediction of HER2-Zero, -Low, and -Positive Breast Cancers. Radiology, 2023, 308, .	7.3	12
64	Rare HER2 L796P missense mutation promotes the growth and oncogenic signaling in breast cancer cells. Proteomics - Clinical Applications, 2024, 18, .	1.6	0
66	A novel nanobody-based HER2-targeting antibody exhibits potent synergistic antitumor efficacy in trastuzumab-resistant cancer cells. Frontiers in Immunology, 0, 14, .	4.8	0
67	Efficacy of Pyrotinib With/Without Trastuzumab in Treatment-Refractory, HER2-Positive Metastatic Colorectal Cancer: Result From a Prospective Observational Study. Clinical Colorectal Cancer, 2024, 23, 58-66.	2.3	0
68	Identification and validation of <i>NCBP1</i> as prognostic and immune-associated biomarkers in breast cancer patients. Journal of Cellular and Molecular Medicine, 2024, 28, .	3.6	0
69	Rational Identification of Novel Antibody-Drug Conjugate with High Bystander Killing Effect against Heterogeneous Tumors. Advanced Science, 2024, 11, .	11.2	0
70	Cuproptosis-related genes predict prognosis and trastuzumab therapeutic response in HER2-positive breast cancer. Scientific Reports, 2024, 14, .	3.3	0
71	Improving HER2-Positive Breast Cancer Targeted Therapy Prediction Using multiMSnet: A Multi-Scale Pathological Image-Based Approach. , 2023, , .		0
72	Effectiveness of [67Cu]Cu-trastuzumab as a theranostic against HER2-positive breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 0, , .	6.4	0
73	A Multifunctional Bimetallic Nanoplatfrom for Synergic Local Hyperthermia and Chemotherapy Targeting HER2-Positive Breast Cancer. Advanced Science, 2024, 11, .	11.2	0
74	Clinical sequencing defines the somatic and germline mutation landscapes of Chinese HER2-Low Breast Cancer. Cancer Letters, 2024, 588, 216763.	7.2	0

#	ARTICLE	IF	CITATIONS
75	Efficacy and safety of trastuzumab deruxtecan in treating human epidermal growth factor receptor 2-low/positive advanced breast cancer:A meta-analysis of randomized controlled trials. Critical Reviews in Oncology/Hematology, 2024, 196, 104305.	4.4	0
76	Evaluating a targeted Palbociclib-Trastuzumab loaded smart niosome platform for treating HER2 positive breast cancer cells. International Journal of Pharmaceutics: X, 2024, 7, 100237.	1.6	0
77	A pilot trial of neoadjuvant pyrotinib plus trastuzumab, dalpiciclib, and letrozole for tripleâ€positive breast cancer. MedComm, 2024, 5, .	7.2	0